抗生物質の市場規模、シェア、動向分析レポート:作用機序別(細胞壁合成阻害剤、RNA合成阻害剤)、薬効クラス別(ペニシリン、セファロスポリン)、タイプ別(ブランド、ジェネリック)、セグメント別予測、2024年~2030年Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporin), By Type (Branded, Generic), And Segment Forecasts, 2024 - 2030 抗生物質市場の成長と動向 Grand View Research, Inc.の最新レポートによると、世界の抗生物質市場規模は2024年から2030年にかけて年平均成長率4.2%を記録し、2030年には680億3000万米ドルに達すると予測され... もっと見る
1~3営業日
サマリー抗生物質市場の成長と動向Grand View Research, Inc.の最新レポートによると、世界の抗生物質市場規模は2024年から2030年にかけて年平均成長率4.2%を記録し、2030年には680億3000万米ドルに達すると予測されている。高い需要、抗生物質耐性プログラムへの注目の高まり、抗生物質の誤用を避けるための取り組み、ジェネリック医薬品の容易な入手が市場成長の要因となっている。抗生物質の購入プロセスは主に医師の影響を受ける。複数のジェネリック医薬品が入手可能なため、購入者は簡単に切り替えることができる。医療機関向けビジネスの場合、価格割引が選択手順において重要な役割を果たす。これにより、市場関係者の利益率はさらに低下する。しかし、ブランド品や特許製品では、買い手にはこうした特権はない。 さらに、規制当局はフルオロキノロンの使用を制限するガイドラインを発表している。したがって、予測期間中、バイヤーの交渉力は低いと予想される。State of World's Antibiotics(世界の抗生物質事情)」レポートによると、2021年、インドにおける抗菌薬使用量は全体で30%急増する。さらに、CDCのAntibiotics Usage in United States report, 2021 updateによると、米国の小売薬局では約2,500万件の処方箋が調剤されている。その中で、アジスロマイシンは2021年に処方された主要な製剤であった。このように、抗菌薬の消費パターンの増加は、予測期間中の市場成長を促進すると思われる。新製品の承認と上市が市場成長を後押しすると予想される。 例えば、2020年6月に米国FDAは、人工呼吸器関連細菌性肺炎および院内細菌性肺炎の治療薬として、シラスタチン-イミペネムとレリバクタムの配合剤であるRecarbrioの承認を発表した。同製品は2019年7月、腹腔内感染症および尿路感染症(UTI)の適応で初めて承認された。今後数年間は、Generating Antibiotics Incentives Now Act、Global Research on Antimicrobial Resistance (GRAM) Project、Global Antibiotic Research & Development Partnership (GARDP)などの政府施策が市場成長を牽引すると予測される。さらに、これらの組織は、最先端の先端医薬品の開発プロセスを推進し、抗生物質医薬品の承認プロセスを円滑化すると予想される。 抗生物質市場レポートハイライト - 新しく開発された抗生物質の商業的成功が乏しいため、政府・非政府機関は抗菌薬の研究開発活動にインセンティブを与える特定の戦略を実施 - 例えば、BARDAとの政府提携は、感染症に対する新規治療法の研究開発活動を促進するために様々な企業を支援している。BARDAは、アストラゼネカやGSK plcのような複数の製薬会社と提携している。 - 細胞壁合成阻害剤セグメントは、グラム陽性菌とグラム陰性菌に対する幅広い活性スペクトルのため、2023年に最大のシェアを占めた。 - RNA合成阻害剤セグメントは、製品上市と研究開発イニシアチブの急増により、2024年から2030年にかけて最も速いCAGRを記録すると予想される。 - ジェネリック医薬品の価格が手頃であることと、ジェネリック医薬品を採用する政府の取り組みにより、2023年にはジェネリック医薬品分野が最大のシェアを占める - 2023年の市場はペニシリン系が牽引。しかし、2024年から2030年までのCAGRはセファロスポリンセグメントが最も速いと予測される - アジア太平洋地域は、大手企業による投資の増加とジェネリック抗生物質の高い採用率により、予測期間中に最も速いCAGRを示すと予想される 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Drug Class 1.2.2. Type 1.2.3. Action Mechanism 1.2.4. Regional scope 1.2.5. Estimates and forecasts timeline 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.4.5.1. Data for primary interviews in North America 1.4.5.2. Data for primary interviews in Europe 1.4.5.3. Data for primary interviews in Asia Pacific 1.4.5.4. Data for primary interviews in Latin America 1.4.5.5. Data for Primary interviews in MEA 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Drug Class 2.2.2. Type 2.2.3. Action Mechanism 2.2.4. Regional outlook 2.3. Competitive Insights Chapter 3. Antibiotics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Development of advanced products 3.2.1.2. Increasing prevalence of infectious diseases 3.2.1.3. Growing collaborations for development of antibiotics 3.2.2. Market restraint analysis 3.2.2.1. High number of patent expirations 3.2.2.2. High R&D cost 3.3. Antibiotics Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier power 3.3.1.2. Buyer power 3.3.1.3. Substitution threat 3.3.1.4. Threat of new entrant 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political landscape 3.3.2.2. Technological landscape 3.3.2.3. Economic landscape Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis 4.1. Drug Class Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Antibiotics Market by Drug Class Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 4.4.1. Cephalosporin 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2. Penicillin 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.3. Fluoroquinolone 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.4. Macrolides 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.5. Carbapenems 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.6. Aminoglycosides 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.7. Sulfonamides 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.8. 7-ACA 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.9. Others 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis 5.1. Type Market Share, 2023 & 2030 5.2. Segment Dashboard 5.3. Global Antibiotics Market by Type Outlook 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 5.4.1. Branded Antibiotics 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 5.4.2. Generic Antibiotics 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis 6.1. Action Mechanism Market Share, 2023 & 2030 6.2. Segment Dashboard 6.3. Global Antibiotics Market by Action Mechanism Outlook 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 6.4.1. Cell Wall Synthesis Inhibitors 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million) 6.4.2. Protein Synthesis Inhibitors 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.3. DNA Synthesis Inhibitors 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.4. RNA Synthesis Inhibitors 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.5. Mycolic Acid Inhibitors 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.6. Others 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030: 7.5. North America 7.5.1. U.S. 7.5.1.1. Key country dynamics 7.5.1.2. Regulatory framework/ reimbursement structure 7.5.1.3. Competitive scenario 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) 7.5.2. Canada 7.5.2.1. Key country dynamics 7.5.2.2. Regulatory framework/ reimbursement structure 7.5.2.3. Competitive scenario 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) 7.6. Europe 7.6.1. UK 7.6.1.1. Key country dynamics 7.6.1.2. Regulatory framework/ reimbursement structure 7.6.1.3. Competitive scenario 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) 7.6.2. Germany 7.6.2.1. Key country dynamics 7.6.2.2. Regulatory framework/ reimbursement structure 7.6.2.3. Competitive scenario 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) 7.6.3. France 7.6.3.1. Key country dynamics 7.6.3.2. Regulatory framework/ reimbursement structure 7.6.3.3. Competitive scenario 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) 7.6.4. Italy 7.6.4.1. Key country dynamics 7.6.4.2. Regulatory framework/ reimbursement structure 7.6.4.3. Competitive scenario 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) 7.6.5. Spain 7.6.5.1. Key country dynamics 7.6.5.2. Regulatory framework/ reimbursement structure 7.6.5.3. Competitive scenario 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) 7.6.6. Norway 7.6.6.1. Key country dynamics 7.6.6.2. Regulatory framework/ reimbursement structure 7.6.6.3. Competitive scenario 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) 7.6.7. Sweden 7.6.7.1. Key country dynamics 7.6.7.2. Regulatory framework/ reimbursement structure 7.6.7.3. Competitive scenario 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) 7.6.8. Denmark 7.6.8.1. Key country dynamics 7.6.8.2. Regulatory framework/ reimbursement structure 7.6.8.3. Competitive scenario 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) 7.7. Asia Pacific 7.7.1. Japan 7.7.1.1. Key country dynamics 7.7.1.2. Regulatory framework/ reimbursement structure 7.7.1.3. Competitive scenario 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) 7.7.2. China 7.7.2.1. Key country dynamics 7.7.2.2. Regulatory framework/ reimbursement structure 7.7.2.3. Competitive scenario 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) 7.7.3. India 7.7.3.1. Key country dynamics 7.7.3.2. Regulatory framework/ reimbursement structure 7.7.3.3. Competitive scenario 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) 7.7.4. Australia 7.7.4.1. Key country dynamics 7.7.4.2. Regulatory framework/ reimbursement structure 7.7.4.3. Competitive scenario 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) 7.7.5. South Korea 7.7.5.1. Key country dynamics 7.7.5.2. Regulatory framework/ reimbursement structure 7.7.5.3. Competitive scenario 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) 7.7.6. Thailand 7.7.6.1. Key country dynamics 7.7.6.2. Regulatory framework/ reimbursement structure 7.7.6.3. Competitive scenario 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) 7.8. Latin America 7.8.1. Brazil 7.8.1.1. Key country dynamics 7.8.1.2. Regulatory framework/ reimbursement structure 7.8.1.3. Competitive scenario 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) 7.8.2. Mexico 7.8.2.1. Key country dynamics 7.8.2.2. Regulatory framework/ reimbursement structure 7.8.2.3. Competitive scenario 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) 7.8.3. Argentina 7.8.3.1. Key country dynamics 7.8.3.2. Regulatory framework/ reimbursement structure 7.8.3.3. Competitive scenario 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) 7.9. MEA 7.9.1. South Africa 7.9.1.1. Key country dynamics 7.9.1.2. Regulatory framework/ reimbursement structure 7.9.1.3. Competitive scenario 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) 7.9.2. Saudi Arabia 7.9.2.1. Key country dynamics 7.9.2.2. Regulatory framework/ reimbursement structure 7.9.2.3. Competitive scenario 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) 7.9.3. UAE 7.9.3.1. Key country dynamics 7.9.3.2. Regulatory framework/ reimbursement structure 7.9.3.3. Competitive scenario 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) 7.9.4. Kuwait 7.9.4.1. Key country dynamics 7.9.4.2. Regulatory framework/ reimbursement structure 7.9.4.3. Competitive scenario 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Key company market share analysis, 2023 8.3.4. AbbVie, Inc. 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Product benchmarking 8.3.4.4. Strategic initiatives 8.3.5. Pfizer Inc. 8.3.5.1. Company overview 8.3.5.2. Financial performance 8.3.5.3. Product benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Novartis AG 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Product benchmarking 8.3.6.4. Strategic initiatives 8.3.7. Merck & Co., Inc. 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Product benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Teva Pharmaceutical Industries Ltd. 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Product benchmarking 8.3.8.4. Strategic initiatives 8.3.9. Lupin Pharmaceuticals, Inc. 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Product benchmarking 8.3.9.4. Strategic initiatives 8.3.10. Viatris, Inc. 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Product benchmarking 8.3.10.4. Strategic initiatives 8.3.11. Melinta Therapeutics LLC 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Product benchmarking 8.3.11.4. Strategic initiatives 8.3.12. Cipla, Inc. 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Product benchmarking 8.3.12.4. Strategic initiatives 8.3.13. Shionogi & Co., Ltd. 8.3.13.1. Company overview 8.3.13.2. Financial performance 8.3.13.3. Product benchmarking 8.3.13.4. Strategic initiatives 8.3.14. KYORIN Pharmaceutical Co., Ltd. 8.3.14.1. Company overview 8.3.14.2. Financial performance 8.3.14.3. Product benchmarking 8.3.14.4. Strategic initiatives 8.3.15. GSK plc 8.3.15.1. Company overview 8.3.15.2. Financial performance 8.3.15.3. Product benchmarking 8.3.15.4. Strategic initiatives 8.3.16. Nabriva Therapeutics PLC 8.3.16.1. Company overview 8.3.16.2. Financial performance 8.3.16.3. Product benchmarking 8.3.16.4. Strategic initiatives
SummaryAntibiotics Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Drug Class 1.2.2. Type 1.2.3. Action Mechanism 1.2.4. Regional scope 1.2.5. Estimates and forecasts timeline 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.4.5.1. Data for primary interviews in North America 1.4.5.2. Data for primary interviews in Europe 1.4.5.3. Data for primary interviews in Asia Pacific 1.4.5.4. Data for primary interviews in Latin America 1.4.5.5. Data for Primary interviews in MEA 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Drug Class 2.2.2. Type 2.2.3. Action Mechanism 2.2.4. Regional outlook 2.3. Competitive Insights Chapter 3. Antibiotics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Development of advanced products 3.2.1.2. Increasing prevalence of infectious diseases 3.2.1.3. Growing collaborations for development of antibiotics 3.2.2. Market restraint analysis 3.2.2.1. High number of patent expirations 3.2.2.2. High R&D cost 3.3. Antibiotics Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Supplier power 3.3.1.2. Buyer power 3.3.1.3. Substitution threat 3.3.1.4. Threat of new entrant 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political landscape 3.3.2.2. Technological landscape 3.3.2.3. Economic landscape Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis 4.1. Drug Class Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Antibiotics Market by Drug Class Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 4.4.1. Cephalosporin 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2. Penicillin 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.3. Fluoroquinolone 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.4. Macrolides 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.5. Carbapenems 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.6. Aminoglycosides 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.7. Sulfonamides 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.8. 7-ACA 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.9. Others 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis 5.1. Type Market Share, 2023 & 2030 5.2. Segment Dashboard 5.3. Global Antibiotics Market by Type Outlook 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 5.4.1. Branded Antibiotics 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million) 5.4.2. Generic Antibiotics 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis 6.1. Action Mechanism Market Share, 2023 & 2030 6.2. Segment Dashboard 6.3. Global Antibiotics Market by Action Mechanism Outlook 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 6.4.1. Cell Wall Synthesis Inhibitors 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million) 6.4.2. Protein Synthesis Inhibitors 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.3. DNA Synthesis Inhibitors 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.4. RNA Synthesis Inhibitors 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.5. Mycolic Acid Inhibitors 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million) 6.4.6. Others 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030: 7.5. North America 7.5.1. U.S. 7.5.1.1. Key country dynamics 7.5.1.2. Regulatory framework/ reimbursement structure 7.5.1.3. Competitive scenario 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) 7.5.2. Canada 7.5.2.1. Key country dynamics 7.5.2.2. Regulatory framework/ reimbursement structure 7.5.2.3. Competitive scenario 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) 7.6. Europe 7.6.1. UK 7.6.1.1. Key country dynamics 7.6.1.2. Regulatory framework/ reimbursement structure 7.6.1.3. Competitive scenario 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) 7.6.2. Germany 7.6.2.1. Key country dynamics 7.6.2.2. Regulatory framework/ reimbursement structure 7.6.2.3. Competitive scenario 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) 7.6.3. France 7.6.3.1. Key country dynamics 7.6.3.2. Regulatory framework/ reimbursement structure 7.6.3.3. Competitive scenario 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) 7.6.4. Italy 7.6.4.1. Key country dynamics 7.6.4.2. Regulatory framework/ reimbursement structure 7.6.4.3. Competitive scenario 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) 7.6.5. Spain 7.6.5.1. Key country dynamics 7.6.5.2. Regulatory framework/ reimbursement structure 7.6.5.3. Competitive scenario 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) 7.6.6. Norway 7.6.6.1. Key country dynamics 7.6.6.2. Regulatory framework/ reimbursement structure 7.6.6.3. Competitive scenario 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) 7.6.7. Sweden 7.6.7.1. Key country dynamics 7.6.7.2. Regulatory framework/ reimbursement structure 7.6.7.3. Competitive scenario 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) 7.6.8. Denmark 7.6.8.1. Key country dynamics 7.6.8.2. Regulatory framework/ reimbursement structure 7.6.8.3. Competitive scenario 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) 7.7. Asia Pacific 7.7.1. Japan 7.7.1.1. Key country dynamics 7.7.1.2. Regulatory framework/ reimbursement structure 7.7.1.3. Competitive scenario 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) 7.7.2. China 7.7.2.1. Key country dynamics 7.7.2.2. Regulatory framework/ reimbursement structure 7.7.2.3. Competitive scenario 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) 7.7.3. India 7.7.3.1. Key country dynamics 7.7.3.2. Regulatory framework/ reimbursement structure 7.7.3.3. Competitive scenario 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) 7.7.4. Australia 7.7.4.1. Key country dynamics 7.7.4.2. Regulatory framework/ reimbursement structure 7.7.4.3. Competitive scenario 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) 7.7.5. South Korea 7.7.5.1. Key country dynamics 7.7.5.2. Regulatory framework/ reimbursement structure 7.7.5.3. Competitive scenario 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) 7.7.6. Thailand 7.7.6.1. Key country dynamics 7.7.6.2. Regulatory framework/ reimbursement structure 7.7.6.3. Competitive scenario 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) 7.8. Latin America 7.8.1. Brazil 7.8.1.1. Key country dynamics 7.8.1.2. Regulatory framework/ reimbursement structure 7.8.1.3. Competitive scenario 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) 7.8.2. Mexico 7.8.2.1. Key country dynamics 7.8.2.2. Regulatory framework/ reimbursement structure 7.8.2.3. Competitive scenario 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) 7.8.3. Argentina 7.8.3.1. Key country dynamics 7.8.3.2. Regulatory framework/ reimbursement structure 7.8.3.3. Competitive scenario 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) 7.9. MEA 7.9.1. South Africa 7.9.1.1. Key country dynamics 7.9.1.2. Regulatory framework/ reimbursement structure 7.9.1.3. Competitive scenario 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) 7.9.2. Saudi Arabia 7.9.2.1. Key country dynamics 7.9.2.2. Regulatory framework/ reimbursement structure 7.9.2.3. Competitive scenario 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) 7.9.3. UAE 7.9.3.1. Key country dynamics 7.9.3.2. Regulatory framework/ reimbursement structure 7.9.3.3. Competitive scenario 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) 7.9.4. Kuwait 7.9.4.1. Key country dynamics 7.9.4.2. Regulatory framework/ reimbursement structure 7.9.4.3. Competitive scenario 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Key company market share analysis, 2023 8.3.4. AbbVie, Inc. 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Product benchmarking 8.3.4.4. Strategic initiatives 8.3.5. Pfizer Inc. 8.3.5.1. Company overview 8.3.5.2. Financial performance 8.3.5.3. Product benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Novartis AG 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Product benchmarking 8.3.6.4. Strategic initiatives 8.3.7. Merck & Co., Inc. 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Product benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Teva Pharmaceutical Industries Ltd. 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Product benchmarking 8.3.8.4. Strategic initiatives 8.3.9. Lupin Pharmaceuticals, Inc. 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Product benchmarking 8.3.9.4. Strategic initiatives 8.3.10. Viatris, Inc. 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Product benchmarking 8.3.10.4. Strategic initiatives 8.3.11. Melinta Therapeutics LLC 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Product benchmarking 8.3.11.4. Strategic initiatives 8.3.12. Cipla, Inc. 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Product benchmarking 8.3.12.4. Strategic initiatives 8.3.13. Shionogi & Co., Ltd. 8.3.13.1. Company overview 8.3.13.2. Financial performance 8.3.13.3. Product benchmarking 8.3.13.4. Strategic initiatives 8.3.14. KYORIN Pharmaceutical Co., Ltd. 8.3.14.1. Company overview 8.3.14.2. Financial performance 8.3.14.3. Product benchmarking 8.3.14.4. Strategic initiatives 8.3.15. GSK plc 8.3.15.1. Company overview 8.3.15.2. Financial performance 8.3.15.3. Product benchmarking 8.3.15.4. Strategic initiatives 8.3.16. Nabriva Therapeutics PLC 8.3.16.1. Company overview 8.3.16.2. Financial performance 8.3.16.3. Product benchmarking 8.3.16.4. Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(アレルギー用薬)の最新刊レポート
Grand View Research 社の最新刊レポート
本レポートと同じKEY WORD(antibiotics)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/06 10:27 153.85 円 167.37 円 202.23 円 |